The round, which brings Montara's total seed funding to $28 million, includes increased participation from all existing investors, including founding investor SV Health Investors' Dementia Discovery Fund, Two Bear Capital, Dolby Family Ventures, and KdT Ventures, along with new investments from BEVC and additional investors.

Montara Therapeutics is a preclinical-stage biopharmaceutical company pursuing novel approaches to develop safer and more efficacious treatments for neurological diseases. Montara's BrainOnly™ platform enables brain-specific pharmacology by leveraging existing and novel chemical warheads, restricting deleterious on-target / off-tissue peripheral activity. BrainOnly holds the potential to drug numerous targets previously considered undruggable greatly expanding the therapeutic options for patients in need of these therapies.